Patents Assigned to eFFECTOR THERAPEUTICS, INC.
-
Patent number: 11952375Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: September 24, 2021Date of Patent: April 9, 2024Assignee: eFFECTOR Therapeutics Inc.Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
-
Patent number: 11878015Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.Type: GrantFiled: August 6, 2021Date of Patent: January 23, 2024Assignee: eFFECTOR Therapeutics Inc.Inventors: Justin T Ernst, Paul A. Sprengeler, Siegfried H. Reich, Samuel Sperry
-
Patent number: 11576933Abstract: The present disclosure provides compositions and methods for improving an antitumor response against non-inflamed solid tumors. Methods of this disclosure include use of an eIF4A inhibitor to promote infiltration of antitumor lymphocytes into a non inflamed solid tumor. Methods of treating cancer associated with a non-inflamed solid tumor are also provided.Type: GrantFiled: May 24, 2018Date of Patent: February 14, 2023Assignee: eFFECTOR Therapeutics Inc.Inventors: Peggy A. Thompson, Kevin R. Webster
-
Patent number: 11564947Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.Type: GrantFiled: September 18, 2020Date of Patent: January 31, 2023Assignee: eFFECTOR Therapeutics Inc.Inventors: Kevin R. Webster, Rajesh Sharma, Gary Chiang
-
Patent number: 11440917Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: February 28, 2020Date of Patent: September 13, 2022Assignee: EFFECTOR THERAPEUTICS, INC.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels
-
Patent number: 11286268Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: June 30, 2020Date of Patent: March 29, 2022Assignee: eFFECTOR Therapeutics, Inc.Inventors: Samuel Sperry, Alan X. Xiang, Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Mike Shaghafi, Theo Michels, Christian Nilewski, Chinh Viet Tran, Garrick Kenneth Packard, Alan Grubbs, Kaveri Urkalan, Takasuke Mukaiyama
-
Patent number: 11130757Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: October 23, 2019Date of Patent: September 28, 2021Assignee: eFFECTOR Therapeutics Inc.Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
-
Patent number: 11083727Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.Type: GrantFiled: December 27, 2018Date of Patent: August 10, 2021Assignee: eFFECTOR Therapeutics Inc.Inventors: Justin T. Ernst, Paul A. Sprengeler, Siegfried H. Reich, Samuel Sperry
-
Patent number: 11014926Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I. or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2. A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b and R10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: April 9, 2019Date of Patent: May 25, 2021Assignee: eFFECTOR Therapeutics, Inc.Inventors: Paul A. Sprengeler, Siegfried H. Reich, Justin T. Ernst, Stephen E Webber
-
Patent number: 10793551Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, Y1, Y2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: October 17, 2018Date of Patent: October 6, 2020Assignee: eFFECTOR Therapeutics Inc.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Alan X. Xiang
-
Patent number: 10780119Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.Type: GrantFiled: May 24, 2018Date of Patent: September 22, 2020Assignee: eFFECTOR Therapeutics Inc.Inventors: Kevin R. Webster, Rajesh Sharma, Gary Chiang
-
Patent number: 10702526Abstract: The present disclosure relates to the use MNK-specific inhibitors to inhibit immunosuppression components, such as immune checkpoint proteins PD-1, PD-L1, LAG3, and/or immunosuppressive cytokines, such as IL-10, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease.Type: GrantFiled: April 15, 2016Date of Patent: July 7, 2020Assignee: eFFECTOR Therapeutics Inc.Inventors: Kevin R. Webster, Vikas Goel
-
Patent number: 10576098Abstract: The present disclosure relates to compositions and methods for treating or preventing a fibrotic disorder or disease.Type: GrantFiled: May 7, 2018Date of Patent: March 3, 2020Assignee: eFFECTOR Therapeutics Inc.Inventors: James Appleman, Peggy A. Thompson
-
Patent number: 10577378Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: March 12, 2018Date of Patent: March 3, 2020Assignee: eFFECTOR Therapeutics, Inc.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels
-
Publication number: 20190119256Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, Y1, Y2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: October 17, 2018Publication date: April 25, 2019Applicant: eFFECTOR Therapeutics, Inc.Inventors: Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Alan X. XIANG
-
Patent number: 10112955Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: October 28, 2016Date of Patent: October 30, 2018Assignee: eFFECTOR Therapeutics, Inc.Inventors: Paul A. Sprengeler, Siegfried H. Reich, Justin T. Ernst, Stephen E. Webber, Mike Shaghafi, Douglas Murphy, Chinh Tran
-
Publication number: 20180298017Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: March 12, 2018Publication date: October 18, 2018Applicant: eFFECTOR Therapeutics, Inc.Inventors: Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan X. XIANG, Christian NILEWSKI, Theo MICHELS
-
Patent number: 10000487Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A1, A2, A3, A4, W1, W2, Y, X, R1, R2, R3, R4a, R4b, R5a, R5b, R6, R7, R8, R9, R9a, R9b, R10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: November 18, 2016Date of Patent: June 19, 2018Assignee: eFFECTOR Therapeutics, Inc.Inventors: Paul A. Sprengeler, Seigfried H. Reich, Stephen E. Webber, Justin T. Ernst
-
Patent number: 9993494Abstract: The present disclosure relates to compositions and methods for treating or preventing a fibrotic disorder or disease.Type: GrantFiled: February 7, 2015Date of Patent: June 12, 2018Assignee: eFFECTOR Therapeutics, Inc.Inventors: James Appleman, Peggy A. Thompson
-
Patent number: 9957277Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: November 22, 2016Date of Patent: May 1, 2018Assignee: eFFECTOR Therapeutics, Inc.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels